OR WAIT null SECS
January 18, 2023
Article
Each 1-SD increment in HDL-C level was associated with a 14% higher risk of fractures in cohort study of approximately 16,000 community-dwelling healthy adults.
Results of the PREVENT CLOT study indicate use of aspirin was as effective as low-molecular-weight heparin for reducing incidence of mortality in patients hospitalized with a traumatic fracture.
January 10, 2023
A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.
January 04, 2023
Released on January 3, the American College of Physician's living osteoporosis guideline represents the organization's first update on the topic since 2017 and includes 6 specific recommendations for pharmacologic management of osteoporosis or low bone mass.
December 20, 2022
Announced by Radius Health on December 20, the US FDA approval for abaloparatide (Tymlos) indicates the agent as a treatment to increase bone density in men with osteoporosis at high risk of fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.
November 03, 2022
An analysis of data from the Cancer Prevention Study-II suggests cancer survivors had a more than doubling in risk of frailty-related bone fractures than their counterparts without cancer.
September 12, 2022
A study presented at ASBMR 2022 leveraging data from more than a dozen countries details trends in hip fracture incidence and projects potential incidence increases by 2050.
July 27, 2022
An ancillary study of the landmark VITAL trial provides clinicians with evidence related to the lack of reduction in fracture risk observed with vitamin D3 supplementation in older adults.
June 27, 2022
An analysis of real-world data from more than 6500 patients suggests insulin users had a greater risk of fracture than patients using metformin, but this became attenuated among patients using a combination of insulin and metformin.
June 20, 2022
Data from Sweden national registers provide insight into the increased risk of adverse outcomes, including fracture, cardiovascular events, and mortality risk, associated with primary hyperparathyroidism as well as the apparent reductions in risk achieved by undergoing parathyroidectomy.